Dr. Kenneth Anderson on Combining Immunotherapies in Myeloma

Kenneth Anderson, MD
Published: Wednesday, May 06, 2015



Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.

Pairing lenalidomide and antibodies is just one example of the potential combinations that could be utilized in myeloma, says Anderson. Research is being conducted looking at checkpoint inhibitors used with vaccines as well as paired with lenalidomide or other similar drugs.

The ultimate goal of these combination treatments is to restore memory immune response in patients against their own tumor cells. If this could be achieved a cure is possible in myeloma, says Anderson.



Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.

Pairing lenalidomide and antibodies is just one example of the potential combinations that could be utilized in myeloma, says Anderson. Research is being conducted looking at checkpoint inhibitors used with vaccines as well as paired with lenalidomide or other similar drugs.

The ultimate goal of these combination treatments is to restore memory immune response in patients against their own tumor cells. If this could be achieved a cure is possible in myeloma, says Anderson.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x